Billionaire investor Stanley Druckenmiller just dumped over $30 million into Revolution Medicines, a biotech firm whose stock has skyrocketed 400% in a year—thanks to breakthrough data on its RAS-targeting cancer drug, daraxonrasib. Early results show nearly double the survival rates for advanced pancreatic cancer patients compared to chemo, fueling FDA approval hopes and massive market hype. But with a $10+ billion valuation already pricing in huge future growth, the stock’s risk-reward is now razor-thin—even as the company eyes expansion into lung cancer. It’s a high-stakes bet for aggressive investors: is this the next big thing—or just the last leg of a wild ride?
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
